CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading CVM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.76%172.501.1%$711.75m
GILDGilead Sciences, Inc.
0.09%70.540.9%$695.99m
CELGCelgene Corporation
0.47%134.311.1%$649.60m
REGNRegeneron Pharmaceuticals, Inc.
-1.75%517.332.7%$572.31m
ALXNAlexion Pharmaceuticals, Inc.
-0.13%126.071.9%$521.18m
BIIBBiogen Inc.
-0.09%280.321.2%$500.23m
VRTXVertex Pharmaceuticals Incorporated
-1.50%133.501.9%$279.31m
INCYIncyte Corporation
0.48%136.282.6%$278.87m
CLVSClovis Oncology, Inc.
-1.84%95.0018.0%$249.90m
TSROTESARO, Inc.
-2.16%146.5314.7%$249.01m
ILMNIllumina, Inc.
1.25%185.283.5%$164.61m
BLUEBluebird Bio, Inc.
-5.49%112.0019.3%$162.00m
PBYIPuma Biotechnology, Inc.
1.22%87.5021.1%$145.68m
KITEKite Pharma, Inc.
7.09%100.6616.1%$139.56m
EXASExact Sciences Corporation
2.31%35.5126.3%$130.55m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.,0012QB-E